TY - JOUR
T1 - Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs
AU - Molinaro, Marilisa
AU - Ameri, Pietro
AU - Marone, Giancarlo
AU - Petretta, Mario
AU - Abete, Pasquale
AU - Di Lisa, Fabio
AU - De Placido, Sabino
AU - Bonaduce, Domenico
AU - Tocchetti, Carlo G.
PY - 2015
Y1 - 2015
N2 - Along with the improvement of survival after cancer, cardiotoxicity due to antineoplastic treatments has emerged as a clinically relevant problem. Potential cardiovascular toxicities due to anticancer agents include QT prolongation and arrhythmias, myocardial ischemia and infarction, hypertension and/or thromboembolism, left ventricular (LV) dysfunction, and heart failure (HF). The latter is variable in severity, may be reversible or irreversible, and can occur soon after or as a delayed consequence of anticancer treatments. In the last decade recent advances have emerged in clinical and pathophysiological aspects of LV dysfunction induced by the most widely used anticancer drugs. In particular, early, sensitive markers of cardiac dysfunction that can predict this form of cardiomyopathy before ejection fraction (EF) is reduced are becoming increasingly important, along with novel therapeutic and cardioprotective strategies, in the attempt of protecting cardiooncologic patients from the development of congestive heart failure.
AB - Along with the improvement of survival after cancer, cardiotoxicity due to antineoplastic treatments has emerged as a clinically relevant problem. Potential cardiovascular toxicities due to anticancer agents include QT prolongation and arrhythmias, myocardial ischemia and infarction, hypertension and/or thromboembolism, left ventricular (LV) dysfunction, and heart failure (HF). The latter is variable in severity, may be reversible or irreversible, and can occur soon after or as a delayed consequence of anticancer treatments. In the last decade recent advances have emerged in clinical and pathophysiological aspects of LV dysfunction induced by the most widely used anticancer drugs. In particular, early, sensitive markers of cardiac dysfunction that can predict this form of cardiomyopathy before ejection fraction (EF) is reduced are becoming increasingly important, along with novel therapeutic and cardioprotective strategies, in the attempt of protecting cardiooncologic patients from the development of congestive heart failure.
UR - http://www.scopus.com/inward/record.url?scp=84947474623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947474623&partnerID=8YFLogxK
U2 - 10.1155/2015/138148
DO - 10.1155/2015/138148
M3 - Review article
AN - SCOPUS:84947474623
VL - 2015
JO - BioMed Research International
JF - BioMed Research International
SN - 2314-6133
M1 - 138148
ER -